|Geron Announces Presentations at AACR Annual Meeting|
MENLO PARK, Calif., March 30, 2012 - Geron Corporation (Nasdaq: GERN) today announced two presentations of preclinical data related to imetelstat, the company's telomerase inhibitor, at the Annual Meeting of the American Association for Cancer Research (AACR), to be held from March 31 to April 4, 2012, in Chicago, IL.
The following posters by Geron scientists and academic collaborators will be presented at McCormick Place West (Hall F) on Tuesday, April 3, between 8:00 a.m. - 12:00 p.m. C.T.:
Abstract Number: 3601
Abstract Number: LB-245
Posters will be made available for viewing following the public presentation on the Events page in the Investor Relations section of the company's website at http://ir.geron.com/phoenix.zhtml?c=67323&p=irol-calendar.
Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel, across the blood-brain barrier by targeting low-density lipoprotein receptor-related proteins (LRPs), specifically LRP-1. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. For more information about Geron, visit www.geron.com.
Anna Krassowska, Ph.D.